Drugs / GANULAMERAN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04537949 | Sep 2020 → Mar 2021 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GANULAMERAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650455 ↗ |
| Known as | BNT162b3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04537949 ↗ |
| Modality | Messenger RNA (mRNA) | “BNT162b3, a nucleoside-modified mRNA-based coronavirus disease 2019 (COVID-19) vaccine” PMID 41530185 ↗ Jan 2026 |
| Route | Intramuscular | “administered as intramuscular injection” NCT04537949 ↗ |